

What is claimed is:

1. A melt granulated substantially homogeneous composition comprising:
 - (A) one or more hydrophilic cellulose ether polymers;
 - (B) a hydrophilic melt binder; and
 - (C) a therapeutically active medicament.
2. A composition according to claim 1 wherein the hydrophilic melt binder is a polyethylene glycol.
3. A composition according to claim 2 wherein the polyethylene glycol has an average molecular weight of about 3,000 to about 9,000.
4. A composition according to claim 1 wherein the hydrophilic cellulose ether polymer is selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, sodiumcarboxymethylcellulose, Carbomer, carboxymethylhydroxyethylcellulose and mixtures thereof.
5. A composition according to claim 4 wherein the hydrophilic cellulose ether polymer is hydroxypropylmethylcellulose, methylcellulose, or mixtures thereof.
6. A composition according to claim 5 wherein the hydrophilic cellulose ether polymer is hydroxypropylmethylcellulose.
7. A composition according to claim 1 further comprising an excipient.

8. A composition of claim 7 wherein said excipient is selected from the group consisting of a binder, diluent, disintegrant or lubricant.

9. A composition according to claim 7 comprising a diluent or binder, wherein the diluent or binder is selected from the group consisting of lactose, starches, sodium alginate, dicalcium phosphate hydrate, sugars, acacia, agar, calcium carrageenan, alginic acid, algin, agarose powder, microcrystalline cellulose, collagen, colloidal magnesium silicate, colloidal silicon dioxide, pectin, gelatin, calcium sulfate, ethyl cellulose and polyacrylates.

10. A composition according to claim 1 comprising:

- (A) 10 to 75 wt % of a hydrophilic cellulose ether polymer or a mixture of hydrophilic cellulose ether polymers;
- (B) 10 to 40 wt % of a hydrophilic melt binder; and
- (C) a therapeutically active medicament.

11. A composition according to claim 10 comprising:

- (A) 10 to 60 wt % of a hydrophilic cellulose ether polymer or a mixture of hydrophilic cellulose ether polymers;
- (B) 10 to 30 wt % of a hydrophilic melt binder, and
- (C) a therapeutically active medicament.

12. A composition according to claim 11 comprising:
- (A) 20 to 60 wt % of a hydroxypropylmethylcellulose polymer;
 - (B) 10 to 20 wt % of a hydrophilic melt binder, and
 - (C) a therapeutically active medicament.
13. A composition according to claim 10 wherein the hydrophilic melt binder is a polyethylene glycol (PEG) with an average molecular weight of about 3,000 to 9,000.
14. A composition according to claim 1 wherein the therapeutically active medicament is Citalopram.
15. A composition according to claim 1 wherein the therapeutically active medicament is Escitalopram.
16. A composition according to claim 1 wherein the therapeutically active medicament is Gaboxadol.
17. A solid modified release dosage form prepared by compression of a composition according to claim 1.
18. A modified release dosage form according to claim 17, further comprising an excipient.

19. A modified release dosage form according to claim 17, which is in the form of a tablet.

20. A process for preparing a therapeutically active composition according to claim 1 comprising:

- (1) applying heat to a composition comprising:
 - (A) one or more hydrophilic cellulose ether polymers;
 - (B) a hydrophilic melt binder; and
 - (C) a therapeutically active medicament;
- (2) mixing the mass to provide a substantially homogeneous composition; and
- (3) cooling the composition to room temperature.